{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:54Z","timestamp":1790630394628,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40487-025-00399-3","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:29:46Z","timestamp":1762262986000},"page":"1225-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Treatment: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"13","author":[{"given":"Cora N.","family":"Sternberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aozhou","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh S.","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"399_CR1","unstructured":"The Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer 2024. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html."},{"issue":"1","key":"399_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"399_CR3","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"399_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.21037\/tau-20-960","volume":"10","author":"J Tian","year":"2021","unstructured":"Tian J, Sun J, Fu G, Xu Z, Chen X, Shi Y, et al. Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy? Transl Androl Urol. 2021;10(1):356\u201373.","journal-title":"Transl Androl Urol"},{"issue":"3","key":"399_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","volume":"38","author":"JC Park","year":"2014","unstructured":"Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer. 2014;38(3):80\u2013108.","journal-title":"Curr Probl Cancer"},{"issue":"21","key":"399_CR6","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138.","journal-title":"J Clin Oncol"},{"issue":"22","key":"399_CR7","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1200\/JCO.22.02762","volume":"41","author":"JP Stein","year":"2023","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2023;41(22):3772\u201381.","journal-title":"J Clin Oncol"},{"key":"399_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.912699","volume":"12","author":"G Roviello","year":"2022","unstructured":"Roviello G, Catalano M, Santi R, Santoni M, Galli IC, Amorosi A, et al. Neoadjuvant treatment in muscle-invasive bladder cancer: from the beginning to the latest developments. Front Oncol. 2022;12:912699.","journal-title":"Front Oncol"},{"issue":"35","key":"399_CR9","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1200\/JCO.23.00307","volume":"41","author":"AM Kamat","year":"2023","unstructured":"Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, et al. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the society for immunotherapy of cancer and the international bladder cancer group. J Clin Oncol. 2023;41(35):5437.","journal-title":"J Clin Oncol"},{"issue":"2","key":"399_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Advanced Bladder Cancer Meta-analysis Collaboration","year":"2005","unstructured":"Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202\u20135 (discussion 5-6).","journal-title":"Eur Urol"},{"issue":"3","key":"399_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506\u201313.","journal-title":"Cancer"},{"issue":"17","key":"399_CR12","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432\u20138.","journal-title":"J Clin Oncol"},{"key":"399_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.euros.2025.08.009","volume":"81","author":"S Gupta","year":"2025","unstructured":"Gupta S, Powles T, Kearney M, Panattoni L, Land N, Flottemesch T, et al. Criteria used to determine platinum eligibility in patients with metastatic urothelial carcinoma: results of a physician survey in five European countries. Eur Urol Open Sci. 2025;81:28\u201336.","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"399_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/tau-23-494","volume":"13","author":"T Lan","year":"2024","unstructured":"Lan T, Ran S, Gao M, Li W, He W. A narrative review of management of muscle-invasive bladder cancer perioperative period: will continuous and combined treatment be the new trend? Transl Androl Urol. 2024;13(2):293.","journal-title":"Transl Androl Urol"},{"issue":"02","key":"399_CR15","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.2217\/fon-2019-0611","volume":"16","author":"G Sonpavde","year":"2020","unstructured":"Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, et al. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 2020;16(02):4359\u201368.","journal-title":"Future Oncol"},{"key":"399_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","volume":"39","author":"CJ Hoimes","year":"2021","unstructured":"Hoimes CJ, Bedke J, Loriot Y, Nishiyama H, Fang X, Kataria RS, et al. KEYNOTE-B15\/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39:TPS4587.","journal-title":"J Clin Oncol"},{"issue":"34","key":"399_CR17","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353\u201360.","journal-title":"J Clin Oncol"},{"key":"399_CR18","unstructured":"Perioperative pembrolizumab (MK-3475) plus neoadjuvant chemotherapy versus perioperative placebo plus neoadjuvant chemotherapy for cisplatin-eligible muscle-invasive bladder cancer (MIBC) (MK-3475-866\/KEYNOTE-866) (KEYNOTE-866) [cited 2024 March 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924856."},{"key":"399_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS505","volume":"39","author":"T Powles","year":"2021","unstructured":"Powles T, Meeks JJ, Galsky MD, Van Der Heijden MS, Nishiyama H, Al-Ahmadie HA, et al. A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). J Clin Oncol. 2021;39:TPS505.","journal-title":"J Clin Oncol"},{"key":"399_CR20","unstructured":"Perioperative enfortumab vedotin (EV) plus pembrolizumab (MK-3475) versus neoadjuvant chemotherapy for cisplatin-eligible muscle invasive bladder cancer (MIBC) (MK-3475-B15\/KEYNOTE-B15\/EV-304) [cited 2024 March 6]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04700124."},{"key":"399_CR21","unstructured":"U.S. Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry 2018 [cited 2024 March 14]. Available from: https:\/\/www.fda.gov\/media\/71195\/download."},{"issue":"3","key":"399_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","volume":"20","author":"O Ciani","year":"2017","unstructured":"Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value Health. 2017;20(3):487\u201395.","journal-title":"Value Health"},{"issue":"8","key":"399_CR23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175(8):1389\u201398.","journal-title":"JAMA Intern Med"},{"key":"399_CR24","doi-asserted-by":"publisher","first-page":"TPS579","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS579","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles T, Drakaki A, Teoh JY-C, Grande E, Fontes-Sousa M, Porta C et al. A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D)+ tremelimumab (T)+ enfortumab vedotin (EV) or D+ EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC)(VOLGA). J Clin Oncol. 2022;40:TPS579\u2013TPS579.","journal-title":"J Clin Oncol"},{"issue":"4","key":"399_CR25","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology\u2014a primer. Am J Cancer Res. 2021;11(4):1121\u201331.","journal-title":"Am J Cancer Res"},{"issue":"9178","key":"399_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","volume":"354","author":"Finnbladder NBCSG, de Tratamiento Oncologico CUE, Group EG-U, Group ABCS, Group NCIoCCT","year":"1999","unstructured":"Finnbladder NBCSG, de Tratamiento Oncologico CUE, Group EG-U, Group ABCS, Group NCIoCCT. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. The Lancet. 1999;354(9178):533\u201340.","journal-title":"The Lancet"},{"issue":"16","key":"399_CR27","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"International Collaboration of Trialists, Finnbladder NBCSG, de Tratamiento Oncologico CUE, Group ABCS, Group NCIoCCT","year":"2011","unstructured":"International Collaboration of Trialists, Finnbladder NBCSG, de Tratamiento Oncologico CUE, Group ABCS, Group NCIoCCT. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171.","journal-title":"J Clin Oncol"},{"key":"399_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s10147-012-0447-z","volume":"18","author":"T Koie","year":"2013","unstructured":"Koie T, Ohyama C, Hashimoto Y, Hatakeyama S, Yamamoto H, Yoneyama T, et al. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. Int J Clin Oncol. 2013;18:724\u201330.","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"399_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"H Kitamura","year":"2014","unstructured":"Kitamura H, Tsukamoto T, Shibata T, Masumori N, Fujimoto H, Hirao Y, et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol. 2014;25(6):1192\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"399_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4081\/aiua.2014.4.278","volume":"86","author":"MA Osman","year":"2014","unstructured":"Osman MA, Gabr AM, Elkady MS. Neoadjuvant chemotherapy versus cystectomy in management of stages II, and III urinary bladder cancer. Arch Ital Urol Androl. 2014;86(4):278\u201383.","journal-title":"Arch Ital Urol Androl"},{"issue":"1","key":"399_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euo.2018.02.007","volume":"1","author":"F Anari","year":"2018","unstructured":"Anari F, O\u2019Neill J, Choi W, Chen DY, Haseebuddin M, Kutikov A, et al. Neoadjuvant dose-dense gemcitabine and cisplatin in muscle-invasive bladder cancer: results of a phase 2 trial. Eur Urol Oncol. 2018;1(1):54\u201360.","journal-title":"Eur Urol Oncol"},{"issue":"19","key":"399_CR32","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer. J Clin Oncol. 2018;36(19):1949.","journal-title":"J Clin Oncol"},{"issue":"4","key":"399_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.clgc.2021.02.001","volume":"19","author":"A Challapalli","year":"2021","unstructured":"Challapalli A, Masson S, White P, Dailami N, Pearson S, Rowe E, et al. A single-arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle-invasive transitional cell carcinoma of the urinary bladder. Clin Genitourin Cancer. 2021;19(4):325\u201332.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"399_CR34","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-20-2409","volume":"27","author":"TW Flaig","year":"2021","unstructured":"Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, et al. A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021;27(9):2435\u201341.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"399_CR35","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.4143\/crt.2020.1356","volume":"53","author":"H Shi","year":"2021","unstructured":"Shi H, Zhang W, Bi X, Wang D, Xiao Z, Guan Y, et al. Neoadjuvant chemotherapy-guided bladder-sparing treatment for muscle-invasive bladder cancer: results of a pilot phase II study. Cancer Res Treat. 2021;53(4):1156.","journal-title":"Cancer Res Treat"},{"issue":"23","key":"399_CR36","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","volume":"28","author":"G Basile","year":"2022","unstructured":"Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res. 2022;28(23):5107\u201314.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"399_CR37","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.21.01485","volume":"40","author":"SA Funt","year":"2022","unstructured":"Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40(12):1312\u201322.","journal-title":"J Clin Oncol"},{"issue":"5","key":"399_CR38","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1470-2045(22)00158-9","volume":"23","author":"SA Hussain","year":"2022","unstructured":"Hussain SA, Lester JF, Jackson R, Gornall M, Qureshi M, Elliott A, et al. Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. Lancet Oncol. 2022;23(5):650\u20138.","journal-title":"Lancet Oncol"},{"issue":"18","key":"399_CR39","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40(18):2013\u201322.","journal-title":"J Clin Oncol"},{"issue":"3","key":"399_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","volume":"84","author":"TW Flaig","year":"2023","unstructured":"Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, et al. Long-term outcomes from a phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695). Eur Urol. 2023;84(3):341\u20137.","journal-title":"Eur Urol"},{"issue":"17_suppl","key":"399_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4507","volume":"41","author":"C Pfister","year":"2023","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al. Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG\/AFU V05 VESPER trial. J Clin Oncol. 2023;41(17_suppl):LBA4507-LBA.","journal-title":"J Clin Oncol"},{"issue":"4","key":"399_CR42","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","volume":"7","author":"P Grivas","year":"2024","unstructured":"Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, et al. PrECOG PrE0807: a phase 1b feasibility trial of neoadjuvant nivolumab without and with lirilumab in patients with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based neoadjuvant chemotherapy. Eur Urol Oncol. 2024;7(4):914\u201322.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"399_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25(2):255\u201364.","journal-title":"Lancet Oncol"},{"issue":"19","key":"399_CR44","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391(19):1773\u201386.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"399_CR45","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1200\/JCO.2024.42.16_suppl.4596","volume":"42","author":"R Yang","year":"2024","unstructured":"Yang R, Li T, Zhang S, Zhang S, Guo H. A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer. J Clin Oncol. 2024;42(16_suppl):4596.","journal-title":"J Clin Oncol"},{"key":"399_CR46","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). Validity of surrogate endpoints in oncology: executive summary of rapid report A10\u201305, Version 1.1. 2011. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK198799\/."},{"issue":"10","key":"399_CR47","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","volume":"38","author":"B Grigore","year":"2020","unstructured":"Grigore B, Ciani O, Dams F, Federici C, de Groot S, M\u00f6llenkamp M, et al. Surrogate endpoints in health technology assessment: an international review of methodological guidelines. Pharmacoeconomics. 2020;38(10):1055\u201370.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"399_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz002","volume":"3","author":"W Xie","year":"2019","unstructured":"Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, et al. A systematic review and recommendation for reporting of surrogate endpoint evaluation using meta-analyses. JNCI Cancer Spectr. 2019;3(1):pkz002.","journal-title":"JNCI Cancer Spectr"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00399-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-025-00399-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-025-00399-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:03:14Z","timestamp":1764090194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-025-00399-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s40487-025-00399-3","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Cora N. Sternberg received honoraria from Merck, Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb\/Medarex, Foundation Medicine, Sanofi, Genzyme, Gilead, MSD, Pfizer, Janssen, Roche, Medscape, Tolmar, and UroToday. Patrick Squires, Ritesh S. Kataria, and Haojie Li are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Yan Song, Aozhou Wu, and Yipeng Gao are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, which funded the development and conduct of this study and manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}